Loss of p57 expression and RhoA overexpression are associated with poor survival of patients with hepatocellular carcinoma

Oncology Reports

Volumn 30, Issue 4, 2013, Pages 1707-1714

  Hu, Tinghua ^a   Guo, Hui ^a   Wang, Wenjuan ^a   Yu, Shuo ^a   Han, Lili ^a   Jiang, Lili ^a   Ma, Jiequn ^a   Yang, Chengcheng ^a   Guo, Qianqian ^a   Nan, Kejun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Biomarker; Hepatocellular carcinoma; P57; Ras homology A

Indexed keywords

ALPHA FETOPROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1C; MESSENGER RNA; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR THROMBUS; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P57; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RHOA GTP-BINDING PROTEIN; RNA, MESSENGER; SURVIVAL; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84882649276     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2608     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Pateras IS, Apostolopoulou K, Niforou K, Kotsinas A and Gorgoulis VG: p57KIP2: 'Kip'ing the cell under control. Mol Cancer Res 7: 1902-1919, 2009.
3. Guo H, Lv Y, Tian T, Hu TH, Wang WJ, Sui X, Jiang L, Ruan ZP and Nan KJ: Downregulation of p57 accelerates the growth and invasion of hepatocellular carcinoma. Carcinogenesis 32: 1897-1904, 2011.
4. Lee MH, Reynisdóttir I and Massagué J: Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 9: 639-649, 1995.
5. Malik K and Brown KW: Epigenetic gene deregulation in cancer. Br J Cancer 83: 1583-1588, 2000.
6. Lee MH and Yang HY: Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 58: 1907-1922, 2001.
7. Lee SH, Lee JK, Jin SM, Lee KC, Sohn JH, Chae SW and Kim DH: Expression of cell-cycle regulators (cyclin D1, cyclin E, p27kip1, p57kip2) in papillary thyroid carcinoma. Otolaryngol Head Neck Surg 142: 332-337, 2010.
8. Larson PS, Schlechter BL, King CL, Yang Q, Glass CN, Mack C, Pistey R, de Las Morenas A and Rosenberg CL: CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer 8: 68, 2008.
9. Li JQ, Wu F, Usuki H, Kubo A, Masaki T, Fujita J, Bandoh S, Saoo K, Takeuchi H, Kuriyama S, Ishida T and Imaida K: Loss of p57KIP2 is associated with colorectal carcinogenesis. Int J Oncol 23: 1537-1543, 2003.
10. Jin RJ, Lho Y, Wang Y, Ao M, Revelo MP, Hayward SW, Wills ML, Logan SK, Zhang P and Matusik RJ: Down-regulation of p57Kip2 induces prostate cancer in the mouse. Cancer Res 68: 3601-3608, 2008.
11. Schwarze SR, Shi Y, Fu VX, Watson PA and Jarrard DF: Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene 20: 8184-8192, 2001.
12. Yan Y, Frisén J, Lee MH, Massagué J and Barbacid M: Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev 11: 973-983, 1997.
13. Zhang P, Liégeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA and Elledge SJ: Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 387: 151-158, 1997.
14. Besson A, Assoian RK and Roberts JM: Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors? Nat Rev Cancer 4: 948-955, 2004.
15. Guo H, Tian T, Nan K and Wang W: p57: A multifunctional protein in cancer (Review). Int J Oncol 36: 1321-1329, 2010.
16. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT and Horwitz AR: Cell migration: integrating signals from front to back. Science 302: 1704-1709, 2003.
17. Aspenström P, Fransson A and Saras J: Rho GTPases have diverse effects on the organization of the actin filament system. Biochem J 377: 327-337, 2004.
18. Ridley AJ and Hall A: The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70: 389-399, 1992.
19. Etienne-Manneville S and Hall A: Rho GTPases in cell biology. Nature 420: 629-635, 2002.
20. Gómez del Pulgar T, Benitah SA, Valerón PF, Espina C and Lacal JC: Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays 27: 602-613, 2005.
21. Pan Y, Bi F, Liu N, Xue Y, Yao X , Zheng Y and Fan D: Expression of seven main Rho family members in gastric carcinoma. Biochem Biophys Res Commun 315: 686-691, 2004.
22. Wong CC, Wong CM, Au SL and Ng IO: RhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N'Rho move it. Liver Int 30: 642-656, 2010.
23. Pillé JY, Denoyelle C, Varet J, Bertrand JR, Soria J, Opolon P, Lu H, Pritchard LL, Vannier JP, Malvy C, Soria C and Li H: Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. Mol Ther 11: 267-274, 2005.
24. Fritz G, Just I and Kaina B: Rho GTPases are over-expressed in human tumors. Int J Cancer 81: 682-687, 1999.
25. Lee S and Helfman DM: Cytoplasmic p21Cip1 is involved in Ras-induced inhibition of the ROCK/LIMK/cofi lin pathway. J Biol Chem 279: 1885-1891, 2004.
26. Wang XQ, Lui EL, Cai Q, Ching WY, Liu KS, Poon RT and Fan ST: p27Kip1 promotes migration of metastatic hepatocellular carcinoma cells. Tumour Biol 29: 217-223, 2008.
27. Larrea MD, Hong F, Wander SA, da Silva TG, Helfman D, Lannigan D, Smith JA and Slingerland JM: RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proc Natl Acad Sci USA 106: 9268-9273, 2009.
28. Croft DR and Olson MF: The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol 26: 4612-4627, 2006.
29. Lai JM, Wu S, Huang DY and Chang ZF: Cytosolic retention of phosphorylated extracellular signal-regulated kinase and a Rho-associated kinase-mediated signal impair expression of p21Cip1/Waf1 in phorbol 12-myristate-13- acetate-induced apoptotic cells. Mol Cell Biol 22: 7581-7592, 2002.
30. Mammoto A, Huang S, Moore K, Oh P and Ingber DE: Role of RhoA, mDia, and ROCK in cell shape-dependent control of the Skp2-p27kip1 pathway and the G1/S transition. J Biol Chem 279: 26323-26330, 2004.
31. Sahai E, Ishizaki T, Narumiya S and Treisman R: Transformation mediated by RhoA requires activity of ROCK kinases. Curr Biol 9: 136-145, 1999.
32. Sahai E, Olson MF and Marshall CJ: Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J 20: 755-766, 2001.
33. Zhang S, Tang Q, Xu F, Xue Y, Zhen Z, Deng Y, Liu M, Chen J, Liu S, Qiu M, Liao Z, Li Z, Luo D, Shi F, Zheng Y and Bi F: RhoA regulates G1-S progression of gastric cancer cells by modulation of multiple INK4 family tumor suppressors. Mol Cancer Res 7: 570-580, 2009.
34. Fan GK, Xu F, Yang B and Fujieda S: p57kip2 expression is related to carcinogenesis and tumor progression in laryngeal tissues. Acta Otolaryngol 126: 301-305, 2006.
35. Biaoxue R, Xiguang C, Hua L, Hui M, Shuanying Y, Wei Z, Wenli S and Jie D: Decreased expression of decorin and p57(KIP2) correlates with poor survival and lymphatic metastasis in lung cancer patients. Int J Biol Markers 26: 9-21, 2011.
36. Ma L, Liu YP, Geng CZ, Wang XL, Wang YJ and Zhang XH: Overexpression of RhoA is associated with progression in invasive breast duct carcinoma. Breast J 16: 105-107, 2010.